Safe, sustainable and supporting brighter futures: DSM launches new DHA and ARA powders

Industry News 04/28/2020

4min read

Talking Nutrition Editors

DHA and ARA for optimal infant nutrition

  • DSM has launched two new high-quality lipid powders for infant nutrition, DHASCO®-B and ARASCO® powders — containing a minimum of 110 mg/g DHA (docosahexaenoic acid) or ARA (arachidonic acid) respectively. These powders contain safe and suitable sources of vegetarian DHA omega-3 and ARA omega-6, and can be used in infant and follow-on formulas and growing-up milk products.
  • These powders have been developed to support optimal growth and development during early life, and enable producers to meet the recent expert recommendation for adding both DHA and ARA to infant and follow-on formula.
  • DSM is committed to supporting manufacturers in creating high-quality infant nutrition products with both DHA and ARA to shape healthy futures for infants and children.



Innovative, science-based infant nutrition solutions

DHA and ARA are long-chain polyunsaturated fatty acids (LC-PUFAs) that play a crucial role in infant growth and development.1,2,3,4,5,6,7 In fact, recent findings indicate that these fatty acids have positive effects on a child’s development when provided together and in efficacious levels and ratios during infancy, with infant nutrition experts endorsing the presence of both DHA and ARA in infant and follow-on formula during this critical window of development.8,9,10

DHA supports brain and cognitive development, such as mental adaptability, problem solving and information processing, and vision. ARA may as well play a role in brain and cognitive development, but also in supporting the development of a healthy immune system, bone formation, blood flow and blood vessel function.11,12,13,14,15,16,17,18,19

Introducing new DHA and ARA powders for infant nutrition

DSM supports DHA and ARA supplementation in infant nutrition products. Its new high-quality microbial DHA and ARA powders, DHASCO®-B and ARASCO®, help manufacturers create infant nutrition products that meet optimal levels of these key nutrients and support adequate intakes.

DHASCO®-B and ARASCO® contain microencapsulated life’sDHA® and life’s™ARA oils, safe and suitable sources of vegetarian DHA omega-3 and ARA omega-6. In fact, life’sDHA® and life’s™ARA are two of the most studied LC-PUFAs on the market with more than 234 million infants estimated to have been nourished with these lipids since their introduction in the late 1990s.

As well as supporting longer shelf life of infant nutrition products, due to greater stability, DHASCO®-B and ARASCO® powders have a limited number of formulation ingredients from conventional (non-GM) origin and are free from engineered nanomaterials. For infant nutrition producers looking to incorporate new solutions into their existing formulations, the new powders are designed to be an easy addition to dry blending manufacturing processes, and enable them to develop solutions with higher microbiological quality that effectively support adequate DHA and ARA intakes globally.

Supporting bright futures

The first 1,000 days between the onset of a woman’s pregnancy and her child’s second birthday offer a unique window of opportunity for nutrition to shape healthier futures. It is essential that infants receive the necessary nutrients at appropriate levels to help set them on a path to a long, healthy life. Breastfeeding is the gold standard in infant nutrition, with DHA and ARA naturally found in breast milk.20,21 However, parents — including mothers who cannot or choose not to breastfeed — should have access to safe and reliable infant nutrition products that contain these important nutrients for early life.

The new microbial powders, DHASCO®-B and ARASCO®, combined with DSM’s expertise in infant nutrition, will help manufacturers provide a safe source of essential DHA and ARA for infants and children worldwide.

For more information about DSM’s nutritional lipids portfolio for infant nutrition, click here or contact us to learn more.

Sign up for our newsletter

Stay up-to-date on the latest science, events and market trends

Tags: INDUSTRY NEWSBABIES AND NURSINGNUTRITIONAL LIPIDSR&DESSENTIALS FOR EARLY LIFE
References

[1] Hadley KB, Ryan AS, Forsyth S, Gautier S, Salem N Jr. (2016). The Essentiality of Arachidonic Acid in Infant Development. Nutrients.12;8(4):216.

[2] Richard C, Lewis ED, Field CJ. (2016) Evidence for the essentiality of arachidonic and docosahexaenoic acid in the postnatal maternal and infant diet for the development of the infant's immune system early in life. Appl Physiol Nutr Metab, 41(5):461-75.

[3] Lepping RJ, Honea RA, Martin LE, Liao K, Choi I-Y, Lee P, Papa, VB, Brooks WM, Shaddy DJ, Carlson SE, Colombo J, Gustafson KM (2019) Long‐chain polyunsaturated fatty acid supplementation in the first year of life affects brain function, structure, and metabolism at age nine years. Developmental Psychobiology, 61: 5–16.

[4] Lien EL, Richard C, Hoffman DR. (2017) DHA and ARA addition to infant formula: Current status and future research directions. Prostaglandins Leukot Essent Fatty Acids.128:26-40. Review.

[5] Colombo J, Carlson SE, Cheatham CL, Shaddy DJ, Kerling EH, Thodosoff JM, Gustafson KM, Brez C. (2013) Long-term effects of LCPUFA supplementation on childhood cognitive outcomes. American Journal of Clinical Nutrition, 98: 403-412.

[6] Colombo J, Jill Shaddy D, Kerling EH, Gustafson KM, Carlson SE. (2017). Docosahexaenoic acid (DHA) and arachidonic acid (ARA) balance in developmental outcomes. Prostaglandins Leukot Essent Fatty Acids. 121:52-56.

[7] Richard C, Lewis ED, Field CJ. (2016) Evidence for the essentiality of arachidonic and docosahexaenoic acid in the postnatal maternal and infant diet for the development of the infant's immune system early in life. Appl Physiol Nutr Metab, 41(5):461-75.

[8] Koletzko B, Bergman K, Brenna TJ, Calder PC, Campoy C, Clandinin MT, Colombo J. Daly M, Decsi T, Demmelmair H, Domellöf M, Mis NF, Gonzales-Casanova I, Van Goudoever JB, Hadjipanayis A, Hernell O, Lapillone A, Mader S, Martin CR, Matthäus V, Ramakrishan U, Smuts CM, Strain SJJ, Tanjung C, Tounian P & Carlson SE 2019, “Should Formula for Infants provide arachidonic acid along with docosahexaenoic acid? A position paper of the European Academy of Pediatrics and the Child Health Foundation”. Am J Clin Nutr. 2020.111(1):10-16.

[9] Tounian, P, Bellaïche M, Legrand P. (2019). Pourquoi doit-on craindre les carences lipidiques en pédiatrie ?

Réalités Pédiatriques, Juin 2019.

[10] Nettleton JA & Salem N Jr (2019) International Society for the Study of Fatty Acids and Lipids 2018 Symposium: Arachidonic and docosahexaenoic acids in infant development. Annals of Nutrition & Metabolism, 74: 83–91.

[11] Hadley KB, Ryan AS, Forsyth S, Gautier S, Salem N Jr. (2016). The Essentiality of Arachidonic Acid in Infant Development. Nutrients.12;8(4):216.

[12] Richard C, Lewis ED, Field CJ. (2016) Evidence for the essentiality of arachidonic and docosahexaenoic acid in the postnatal maternal and infant diet for the development of the infant's immune system early in life. Appl Physiol Nutr Metab, 41(5):461-75.

[13] Lepping RJ, Honea RA, Martin LE, Liao K, Choi I-Y, Lee P, Papa, VB, Brooks WM, Shaddy DJ, Carlson SE, Colombo J, Gustafson KM (2019) Long‐chain polyunsaturated fatty acid supplementation in the first year of life affects brain function, structure, and metabolism at age nine years. Developmental Psychobiology, 61: 5–16.

[14] Lien EL, Richard C, Hoffman DR. (2017) DHA and ARA addition to infant formula: Current status and future research directions. Prostaglandins Leukot Essent Fatty Acids.128:26-40. Review.

[15] Nettleton JA & Salem N Jr (2019) International Society for the Study of Fatty Acids and Lipids 2018 Symposium: Arachidonic and docosahexaenoic acids in infant development. Annals of Nutrition & Metabolism, 74: 83–91.

[16] Colombo J, Carlson SE, Cheatham CL, Shaddy DJ, Kerling EH, Thodosoff JM, Gustafson KM, Brez C. (2013) Long-term effects of LCPUFA supplementation on childhood cognitive outcomes. American Journal of Clinical Nutrition, 98: 403-412.

[17] Colombo J, Jill Shaddy D, Kerling EH, Gustafson KM, Carlson SE. (2017). Docosahexaenoic acid (DHA) and arachidonic acid (ARA) balance in developmental outcomes. Prostaglandins Leukot Essent Fatty Acids. 121:52-56.

[18] Hadley KB, Ryan AS, Forsyth S, Gautier S, Salem N Jr. (2016). The Essentiality of Arachidonic Acid in Infant Development. Nutrients.12;8(4):216.

[19] Richard C, Lewis ED, Field CJ. (2016) Evidence for the essentiality of arachidonic and docosahexaenoic acid in the postnatal maternal and infant diet for the development of the infant's immune system early in life. Appl Physiol Nutr Metab, 41(5):461-75.

[20] Brenna TJ, Varamini B, Jensen RG et al.; “Docosahexaenoic acid and arachidonic acid concentrations in human breast milk worldwide”; Am J Clin Nutr. 2007; 85(6):1457-64.

[21] Fu Y, Liu X, Zhou B, Jiang AC, Chai L. (2016) An updated review of worldwide levels of docosahexaenoic and arachidonic acid in human breast milk by region. Public Health Nutrition, 19(15): 2675-2687.

Get Started

Learn how DSM can help your business. Select the options below to connect your needs with the right solution.

If the options above don't sound like you, skip ahead and contact us.